Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Lymphoma

Thiotepa-based high-dose therapy for autologous stem cell transplantation in lymphoma: a retrospective study from the EBMT

Bone Marrow Transplantation volume 51, pages 212–218 (2016)Cite this article

Subjects

Abstract

Clinical information about thiotepa-based autologous stem cell transplantation (auto-SCT) outside the primary central nervous system lymphoma (PCNSL) field is sparse. In this registry-based retrospective study, we evaluated potential risks and benefits of thiotepa-based preparative regimens compared with BEAM (carmustine, etoposide, cytarabine, melphalan) in auto-SCT for diffuse large B-cell lymphoma (DLBCL, excluding PCNSL), follicular lymphoma (FL) or Hodgkin lymphoma (HL). A total of 14 544 patients (589 thiotepa and 13 955 BEAM) met the eligibility criteria, and 535 thiotepa- and 1031 BEAM-treated patients were matched in a 1:2 ratio for final comparison. No significant differences between thiotepa and BEAM groups for any survival end point were identified in the whole sample or disease entity subsets. For a more detailed analysis, 47 TEAM (thiotepa, etoposide, cytarabine, melphalan)-treated patients were compared with 75 matched BEAM patients with additional collection of toxicity data. Again, there were no significant differences between the two groups for any survival end point. In addition, the frequency of common infectious and non-infectious complications including secondary malignancies was comparable between TEAM and BEAM. These results indicate that thiotepa-based high-dose therapy might be a valuable alternative to BEAM in DLBCL, HL and FL. Further evaluation by prospective clinical trials is warranted.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Ljungman P, Bregni M, Brune M, Cornelissen J, de Witte T, Dini G et al. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009. Bone Marrow Transplant 2010; 45: 219–234.

    Article  CAS  Google Scholar 

  2. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540–1545.

    Article  CAS  Google Scholar 

  3. Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 2002; 359: 2065–2071.

    Article  CAS  Google Scholar 

  4. Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010; 28: 4184–4190.

    Article  Google Scholar 

  5. Illerhaus G, Marks R, Ihorst G, Guttenberger R, Ostertag C, Derigs G et al. High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma. J Clin Oncol 2006; 24: 3865–3870.

    Article  CAS  Google Scholar 

  6. Schorb E, Kasenda B, Atta J, Kaun S, Morgner A, Hess G et al. Prognosis of patients with primary central nervous system lymphoma after high-dose chemotherapy followed by autologous stem cell transplantation. Haematologica 2013; 98: 765–770.

    Article  Google Scholar 

  7. Soussain C, Hoang-Xuan K, Taillandier L, Fourme E, Choquet S, Witz F et al. Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Societe Francaise de Greffe de Moelle Osseuse-Therapie Cellulaire. J Clin Oncol 2008; 26: 2512–2518.

    Article  Google Scholar 

  8. Alessandrino EP, Bernasconi P, Colombo A, Caldera D, Martinelli G, Vitulo P et al. Pulmonary toxicity following carmustine-based preparative regimens and autologous peripheral blood progenitor cell transplantation in hematological malignancies. Bone Marrow Transplant 2000; 25: 309–313.

    Article  CAS  Google Scholar 

  9. Korfel A, Elter T, Thiel E, Hanel M, Mohle R, Schroers R et al. Phase II study of central nervous system (CNS)-directed chemotherapy including high-dose chemotherapy with autologous stem cell transplantation for CNS relapse of aggressive lymphomas. Haematologica 2013; 98: 364–370.

    Article  CAS  Google Scholar 

  10. Zaucha R, Gooley T, Holmberg L, Gopal AK, Press O, Maloney D et al. High-dose chemotherapy with BEAM or busulphan/melphalan and thiotepa followed by hematopoietic cell transplantation in malignant lymphoma. Leuk Lymphoma 2008; 49: 1899–1906.

    Article  CAS  Google Scholar 

  11. Ganguly S, Jain V, Divine C, Aljitawi O, Abhyankar S, McGuirk J . BU, melphalan and thiotepa as a preparative regimen for auto-transplantation in Hodgkin's disease. Bone Marrow Transplant 2012; 47: 311–312.

    Article  CAS  Google Scholar 

  12. Lee SC, Kim SJ, Lee DH, Kim WS, Suh C, Won JH . Excessive toxicity of once daily i.v. BU, melphalan and thiotepa followed by auto SCT on patients with non-Hodgkin's lymphoma. Bone Marrow Transplant 2010; 45: 801–802.

    Article  Google Scholar 

  13. Demirer T, Ayli M, Fen T, Ozcan M, Arat M, Buyukberber S et al. High-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous peripheral blood stem cell transplantation in patients with lymphoma—a retrospective evaluation. Bone Marrow Transplant 2004; 34: 781–786.

    Article  CAS  Google Scholar 

  14. Di Ianni M, Ballanti S, Iodice G, Reale A, Falzetti F, Minelli O et al. High-dose thiotepa, etoposide and carboplatin as conditioning regimen for autologous stem cell transplantation in patients with high-risk Hodgkin's lymphoma. Hematology 2012; 17: 23–27.

    Article  CAS  Google Scholar 

  15. Fenske TS, Kahl BS, Eickhoff J, Mitchell TL, Smith EP, Atkinson E et al. Excessive toxicity of the high dose thiotepa and etoposide regimen when combined with radiation: long-term autologous transplantation experience in follicular and mantle cell lymphoma. Leuk Lymphoma 2005; 46: 1441–1448.

    Article  CAS  Google Scholar 

  16. Gutierrez-Delgado F, Holmberg L, Hooper H, Petersdorf S, Press O, Maziarz R et al. Autologous stem cell transplantation for Hodgkin's disease: busulfan, melphalan and thiotepa compared to a radiation-based regimen. Bone Marrow Transplant 2003; 32: 279–285.

    Article  CAS  Google Scholar 

  17. McCoy AG, Smith EP, Atkinson ME, Baranski B, Kahl BS, Juckett M et al. A novel preparative regimen for autologous transplant in non-Hodgkin's lymphoma: long-term experience with etoposide and thiotepa. Bone Marrow Transplant 2004; 33: 19–24.

    Article  CAS  Google Scholar 

  18. Przepiorka D, Nath R, Ippoliti C, Mehra R, Hagemeister F, Diener K et al. A phase I–II study of high-dose thiotepa, busulfan and cyclophosphamide as a preparative regimen for autologous transplantation for malignant lymphoma. Leuk Lymphoma 1995; 17: 427–433.

    Article  CAS  Google Scholar 

  19. Schiffman K, Buckner CD, Maziarz R, Maloney DG, Appelbaum FR, Press O et al. High-dose busulfan, melphalan, and thiotepa followed by autologous peripheral blood stem cell transplantation in patients with aggressive lymphoma or relapsed Hodgkin's disease. Biol Blood Marrow Transplant 1997; 3: 261–266.

    CAS  PubMed  Google Scholar 

  20. Waheed F, Kancherla R, Seiter K, Liu D, Qureshi Z, Hoang A et al. High dose chemotherapy with thiotepa, mitoxantrone and carboplatin (TMJ) followed by autologous stem cell support in 100 consecutive lymphoma patients in a single centre: analysis of efficacy, toxicity and prognostic factors. Leuk Lymphoma 2004; 45: 2253–2259.

    Article  CAS  Google Scholar 

  21. Visani G, Malerba L, Stefani PM, Capria S, Galieni P, Gaudio F et al. BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients. Blood 2011; 118: 3419–3425.

    Article  CAS  Google Scholar 

  22. Visani G, Stefani PM, Capria S, Malerba L, Galieni P, Gaudio F et al. Bendamustine, etoposide, cytarabine, melphalan, and autologous stem cell rescue produce a 72% 3-year PFS in resistant lymphoma. Blood 2014; 124: 3029–3031.

    Article  CAS  Google Scholar 

  23. Heideman RL, Cole DE, Balis F, Sato J, Reaman GH, Packer RJ et al. Phase I and pharmacokinetic evaluation of thiotepa in the cerebrospinal fluid and plasma of pediatric patients: evidence for dose-dependent plasma clearance of thiotepa. Cancer Res 1989; 49: 736–741.

    CAS  PubMed  Google Scholar 

  24. Chamberlain MC . Salvage therapy with bendamustine for methotrexate refractory recurrent primary CNS lymphoma: a retrospective case series. J Neurooncol 2014; 118: 155–162.

    Article  CAS  Google Scholar 

  25. Renfrow JJ, Detroye A, Chan M, Tatter S, Ellis T, McMullen K et al. Initial experience with bendamustine in patients with recurrent primary central nervous system lymphoma: a case report. J Neurooncol 2012; 107: 659–663.

    Article  Google Scholar 

  26. Boehme V, Zeynalova S, Kloess M, Loeffler M, Kaiser U, Pfreundschuh M et al. Incidence and risk factors of central nervous system recurrence in aggressive lymphoma—a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol 2007; 18: 149–157.

    Article  CAS  Google Scholar 

  27. Aggarwal C, Gupta S, Vaughan WP, Saylors GB, Salzman DE, Katz RO et al. Improved outcomes in intermediate- and high-risk aggressive non-Hodgkin lymphoma after autologous hematopoietic stem cell transplantation substituting intravenous for oral busulfan in a busulfan, cyclophosphamide, and etoposide preparative regimen. Biol Blood Marrow Transplant 2006; 12: 770–777.

    Article  CAS  Google Scholar 

  28. Escalon MP, Stefanovic A, Venkatraman A, Pereira D, Santos ES, Goodman M et al. Autologous transplantation for relapsed non-Hodgkin's lymphoma using intravenous busulfan and cyclophosphamide as conditioning regimen: a single center experience. Bone Marrow Transplant 2009; 44: 89–96.

    Article  CAS  Google Scholar 

  29. Kim JG, Sohn SK, Chae YS, Yang DH, Lee JJ, Kim HJ et al. Multicenter study of intravenous busulfan, cyclophosphamide, and etoposide (i.v. Bu/Cy/E) as conditioning regimen for autologous stem cell transplantation in patients with non-Hodgkin's lymphoma. Bone Marrow Transplant 2007; 40: 919–924.

    Article  CAS  Google Scholar 

  30. Yusuf RZ, Dey B, Yeap BY, McAfee S, Attar E, Sepe PS et al. Autologous SCT with a dose-reduced BU and CY regimen in older patients with non-Hodgkin's lymphoma. Bone Marrow Transplant 2009; 43: 37–42.

    Article  CAS  Google Scholar 

  31. Chen YB, Lane AA, Logan BR, Zhu X, Akpek G, Aljurf MD et al. Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant 2015; 21: 1046–1053.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine V, University Hospital Heidelberg, Heidelberg, Germany

    L Sellner & P Dreger

  2. Lymphoma Working Party, European Society for Blood and Marrow Transplantation, Paris, France

    A Boumendil, H Finel, A Sureda & P Dreger

  3. Department of Hematology, Pitié-Salpêtrière Hospital, Paris, France

    S Choquet

  4. University of Napoli, Napoli, Italy

    G de Rosa

  5. University of Perugia, Perugia, Italy

    F Falzetti

  6. Department of Hematology, Azienda Ospedali Riuniti Villa Sofia-Cervello, Palermo, Italy

    R Scime

  7. Department of Hematology, University Hospital Düsseldorf, Oncology and Clinical Immunology, Heinrich Heine University, Düsseldorf, Germany

    G Kobbe

  8. Cardarelli Hospital, Napoli, Italy

    F Ferrara

  9. Service d’Hématologie Clinique, Hôpital Robert Debré, Centre Hospitalier Universitaire (CHU) de Reims, Reims, France

    A Delmer

  10. Department of Hematology and Oncology, Helios Hospital Erfurt, Erfurt, Germany

    H Sayer

  11. APHP, Hopital Saint-louis, Hemato-Oncology Paris Diderot University, Sorbonne Paris Cité, Paris, France

    S Amorim

  12. Hematology Department, Paoli Calmettes Institute, Marseille Aix-Marseille University, Marseille, France

    R Bouabdallah

  13. Department of Hematology, Freiburg University Medical Center, Freiburg, Germany

    J Finke

  14. Hematologie, Hospices Civils de Lyon and Université Claude Bernard Lyon-1, Pierre Bénite, France

    G Salles

  15. Hematology Department and Hematopoietic Stem Cell Transplantation Unit, LIRIC-U995, University-Hospital of Lille, Lille, France

    I Yakoub-Agha

  16. Department of Hemato-Oncology, Faculty Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic

    E Faber

  17. Hematology Department, Centre Leon Berard, Lyon, France

    E Nicolas-Virelizier

  18. Hematology Unit, Arcispedale S Maria Nuova-IRCCS, Reggio Emilia, Italy

    L Facchini

  19. Hematology Unit, Ospedale Civile, Piacenza, Italy

    D Vallisa

  20. Hematology Unit, S Maria delle Croci Hospital, Ravenna, Italy

    E Zuffa

  21. Institut Català d'Oncologia, Hospital Duran i Reynals, Barcelona, Spain

    A Sureda

Authors
  1. L Sellner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A Boumendil
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H Finel
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S Choquet
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. G de Rosa
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. F Falzetti
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. R Scime
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. G Kobbe
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. F Ferrara
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. A Delmer
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. H Sayer
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. S Amorim
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. R Bouabdallah
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. J Finke
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. G Salles
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. I Yakoub-Agha
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. E Faber
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. E Nicolas-Virelizier
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. L Facchini
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. D Vallisa
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. E Zuffa
    View author publications

    You can also search for this author in PubMed Google Scholar

  22. A Sureda
    View author publications

    You can also search for this author in PubMed Google Scholar

  23. P Dreger
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

on behalf of the EBMT Lymphoma Working Party

Corresponding author

Correspondence to L Sellner.

Ethics declarations

Competing interests

This study was supported by a restricted grant from Riemser Pharma, Greifswald, Germany. LS and PD received honoraria from Riemser Pharma, Greifswald, Germany.

Additional information

Presented in part in abstract form at the 17th annual meeting of the European Hematology Association (EHA) (17 June 2012, Amsterdam, Netherlands), the 19th annual meeting of the European Hematology Association (EHA) 2014 (13 June 2014, Milan, Italy), the 40th annual meeting of the European Society for Blood and Marrow Transplantation (EBMT) 2014 (31 March 2014, Milan, Italy) and the annual meeting of the German Society for Hematology and Oncology (DGHO) 2014 (12/13 October 2014, Hamburg, Germany).

Supplementary Information accompanies this paper on Bone Marrow Transplantation website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sellner, L., Boumendil, A., Finel, H. et al. Thiotepa-based high-dose therapy for autologous stem cell transplantation in lymphoma: a retrospective study from the EBMT. Bone Marrow Transplant 51, 212–218 (2016). https://doi.org/10.1038/bmt.2015.273

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2015.273

Search

Advanced search

Quick links